facebook
twitter
rss
account
search
search
Headlines

DHA-rich diet may help curb Alzheimer's

IRVINE, Calif., April 17 (UPI) -- DHA, a type of omega-3 fatty acid found in fish, eggs, organ meats, fortified foods and food supplements, may slow the onset of Alzheimer's disease.

U.S. adults know little about Alzheimer's

NEW YORK, April 16 (UPI) -- A poll finds that while more than half of U.S. adults know someone with Alzheimer's, 90 percent say they don't know much about the disease.

EEG puts early eye on Alzheimer's

WASHINGTON, April 13 (UPI) -- U.S. researchers say electroencephalograms may lead to earlier diagnosis and treatment of Alzheimer's disease.

King may owe Alzheimer's apology

LOS ANGELES, April 12 (UPI) -- A spokesman for Alzheimer's patients said U.S. TV talk show host Larry King may owe an apology for his recent remarks about the disease.

E4 gene main culprit in Alzheimer's

OKLAHOMA CITY, April 11 (UPI) -- Dr. Jordan Tang and others at the Oklahoma Medical Research Foundation have discovered a "molecular mechanism" linking a specific gene to Alzheimer's disease.

Memory Pharma testing Alzheimer's drug

MONTVALE, N.J., April 5 (UPI) -- U.S. firm Memory Pharmaceuticals said Thursday it has finished enrolling patients in a phase 2a trial of its Alzheimer's drug, MEM 1003.

Sedatives killing Alzheimer's patients

LONDON, March 30 (UPI) -- A British report said Alzheimer's patients are dying earlier because of controversial sedatives known as neuroleptics.

Test can detect Alzheimer's in blood

PARIS, March 15 (UPI) -- French firm Exonhit Therapeutics said Thursday it has identified a panel of genes that allow Alzheimer's disease to be diagnosed from a blood test.

New genetic risks found in Alzheimer's

CARDIFF, Wales, March 6 (UPI) -- Welsh scientists have discovered evidence that additional genes might be involved in the development of Alzheimer's disease.

Siemens, Wyeth join on Alzheimer's deal

HOFFMAN ESTATES, Ill., March 5 (UPI) -- U.S. molecular device maker Siemens Medical Solutions and drug firm Wyeth said Monday they have made a deal to co-develop Alzheimer's therapies.

Pipex gets NIH grant for Alzheimers study

ANN ARBOR, Mich., Feb. 15 (UPI) -- U.S. firm Pipex Pharmaceuticals said Thursday it has been awarded a government grant to test its Alzheimer's drug Coprexa.

Leading Alzheimer's researcher dies

SAN DIEGO, Feb. 8 (UPI) -- Dr. Leon Thal, a leading proponent of new therapies for Alzheimer's disease, died in a plane crash near Borrego Springs, Calif. He was 62.

Lonely people twice as likely for Alzheimer's

CHICAGO, Feb. 6 (UPI) -- Lonely people may be twice as likely to develop dementia linked to Alzheimer's disease late in life than those who are not lonely, says a U.S. study.

Alzheimer's brain gets less blood

ROCHESTER, N.Y., Jan. 24 (UPI) -- The two dominant proteins that determine how much blood flows through the body's arteries have been implicated in Alzheimer's disease, say U.S. researchers.

Study: Learning process slows Alzheimer's

IRVINE, Calif., Jan. 24 (UPI) -- A U.S. study suggests the process of learning can slow the development of two brain lesions that are hallmarks of Alzheimer's disease.
Page 14 of 25
Photos
Alzheimer's Disease
Rudolph Tanzi, Ph.D., testifies about Alzheimer's disease before the Senate Special Committee on Aging on Capitol Hill in Washington on May 14, 2008. Tanzi is director of Generics and Aging Research Unit, Mass. General Institute for Neurodegenerative Diseases and professor of neurology at Harvard University. (UPI Photo/Roger L. Wollenberg)
Wiki

Alzheimer's disease (AD), also called Alzheimer disease, Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer's, is the most common form of dementia. This incurable, degenerative, and terminal disease was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him. Generally it is diagnosed in people over 65 years of age, although the less-prevalent early-onset Alzheimer's can occur much earlier. An estimated 26.6 million people worldwide had Alzheimer's in 2006; this number may quadruple by 2050.

Although each sufferer experiences Alzheimer's in a unique way, there are many common symptoms. The earliest observable symptoms are often mistakenly thought to be 'age-related' concerns, or manifestations of stress. In the early stages, the most commonly recognised symptom is memory loss, such as difficulty in remembering recently learned facts. When a doctor or physician has been notified, and AD is suspected, the diagnosis is usually confirmed with behavioural assessments and cognitive tests, often followed by a brain scan if available. As the disease advances, symptoms include confusion, irritability and aggression, mood swings, language breakdown, long-term memory loss, and the general withdrawal of the sufferer as their senses decline. Gradually, bodily functions are lost, ultimately leading to death. Individual prognosis is difficult to assess, as the duration of the disease varies. AD develops for an indeterminate period of time before becoming fully apparent, and it can progress undiagnosed for years. The mean life expectancy following diagnosis is approximately seven years. Fewer than three percent of individuals live more than fourteen years after diagnosis.

The cause and progression of Alzheimer's disease are not well understood. Research indicates that the disease is associated with plaques and tangles in the brain. Currently used treatments offer a small symptomatic benefit; no treatments to delay or halt the progression of the disease are as yet available. As of 2008, more than 500 clinical trials were investigating possible treatments for AD, but it is unknown if any of them will prove successful. Many measures have been suggested for the prevention of Alzheimer's disease, but their value is unproven in slowing the course and reducing the severity of the disease. Mental stimulation, exercise, and a balanced diet are often recommended, as both a possible prevention and a sensible way of managing the disease.

This article is licensed under the GNU Free Documentation License.
It uses material from the Wikipedia article "Alzheimer's Disease."
Most Popular
x
Feedback